

STATEMENT OF PURPOSE

RS29078C1 / S1246

The Idaho Board of Pharmacy administers the regulatory provisions of the state's Uniform Controlled Substances Act. This bill mirrors the federal Drug Enforcement Administration (DEA) controlled substance scheduling decisions for 2021, including placing synthetic opioids in Schedule I, an opiate in schedule II, multiple substances in Schedule IV and an anticonvulsant substance in Schedule V.

FISCAL NOTE

This legislation will have no impact on the state's General fund or any dedicated fund or federal fund because adding, removing, or rescheduling products to the Controlled Substances Act does not create any new state program and does not compel any state action.

Contact:

Senator Melissa Wintrow
(208) 332-1339

DISCLAIMER: This statement of purpose and fiscal note are a mere attachment to this bill and prepared by a proponent of the bill. It is neither intended as an expression of legislative intent nor intended for any use outside of the legislative process, including judicial review (Joint Rule 18).